Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) may be too small for some investors to consider as a tactical investor play. Even valued under $1 billion, its stock is a fraction versus the pre-2010 […]
After the Stock Doubled in August, What’s the Tactical Case Ahead for Rigel Pharmaceuticals?